Oxidative stress reactivates androgen receptor signaling via USP36 to drive castration resistance in prostate cancer
Castration-resistant prostate cancer (CRPC) often emerges within a few years following androgen deprivation therapy, and therapeutic options remain limited. Androgen deprivation induces oxidative stress in prostate cancer (PCa) cells, leading to aberrant activation of androgen receptor (AR) signaling. This study aims to clarify the molecular mechanism underlying oxidative stress-induced AR activation in CRPC. Transcriptional activity of the prostate-specific antigen (PSA) promoter was evaluated using a dual-luciferase reporter assay under various treatments. To identify AR-interacting proteins under oxidative stress, TurboID-mediated proximity biotin labeling coupled with mass spectrometry was employed following H<sub>2</sub>O<sub>2</sub> exposure. Protein-protein interactions between AR and ubiquitin-specific peptidase 36 (USP36) were validated by co-immunoprecipitation (Co-IP). Subcellular AR expression was assessed via Immunofluorescence in PCa cells. Low doses H<sub>2</sub>O<sub>2</sub> (10 and 20 μM) enhanced viability and induced oxidative stress in PCa cells, and these concentrations were therefore selected for subsequent experiments. H<sub>2</sub>O<sub>2</sub> treatment activated the AR-PSA signaling axis. The deubiquitinating enzyme USP36 was identified among the proteins that interact with AR upon H<sub>2</sub>O<sub>2</sub> stimulation. Co-IP confirmed the specific binding between AR and USP36. Functional studies revealed that USP36 deubiquitinates and stabilizes AR. Notably, knockdown of USP36 abolished H<sub>2</sub>O<sub>2-</sub>induced activation of the AR-PSA pathway. H<sub>2</sub>O<sub>2</sub> promotes the interaction between USP36 and AR, resulting in AR stabilization, transcriptional activation of PSA, and conferring androgen resistance. These findings provide mechanistic insights into how oxidative stress reactivates AR signaling in PCa and highlight potential therapeutic strategies for different stages of PCa.
Authors
- Zhiheng Huang
- Bo Zhou (ORCID: https://orcid.org/0000-0003-1063-2493)
- Ning Wang (ORCID: https://orcid.org/0000-0002-9655-9735)
- Changhui Fan
- Yu‐Long Gu (ORCID: https://orcid.org/0000-0001-6317-5658)
- Junfeng Gao
Institutions
- Second Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Scientific Reports
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1038/s41598-025-25964-8
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00